A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

Non Small Cell Lung Cancer Clinical Trial

Official title:

A Phase 2, Open-label Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-line Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00735696
• Other study ID #: 13914
• Secondary ID: 2007-006715-22CP
• Status: Completed
• Phase: Phase 2
• First received: August 13, 2008
• Last updated: December 17, 2014
• Start date: January 2009
• Est. completion date: January 2012

Study information

• Verified date: December 2014
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review BoardUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the progression-free survival (PFS) rate at 6 months of ramucirumab administered in combination with paclitaxel and carboplatin as first-line therapy for Stage IIIB or IV non-small cell lung cancer

Description:

Non-small cell lung cancer (NSCLC) accounts for 75-80% of all lung cancers. The advanced stages are associated with poor survival rates, a median survival rate of approximately 3.9 months if left untreated.

Angiogenesis is a process for wound healing and restoring blood flow to tissues after injury. It is the physiological process involving the growth of new blood vessels from pre-existing vessels. Angiogenesis may be promoted by growth factors and in diseases such as cancer, where growth factors are over expressed, the body loses the ability to maintain a balanced angiogenesis. This may embellish the existing supplies of blood; potentially increasing the delivery of oxygen and nutrients supplies for cancer growth and survival.

Ramucirumab is an angiogenesis inhibitor; and is believed to block the promotion of the growth factor to form new blood vessels, thus reducing the blood supply to the cancer cells.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: January 2012
• Est. primary completion date: October 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed NSCLC

• Advanced NSCLC

• Measurable disease (as defined by Response Evaluation Criteria in Solid Tumors [RECIST 1.0])

• Eastern Cooperative Oncology Group (ECOG) Performance Status is = 1

• Age = 18 years

• Adequate hematologic function = an absolute neutrophil count (ANC) = 1500/µL, hemoglobin = 9 g/dL, and a platelet count = 100,000/microliter (µL)

• Adequate hepatic function = a total bilirubin = 1.5 mg/dL transaminases and alkaline phosphatase = 5 x the upper limit of normal (ULN)

• Adequate renal function serum creatinine = 1.5 x ULN or calculated creatinine clearance (CrCl) > 60 mL/minute, and urine dipstick for protein < 1+ (ie, either 0 or trace)

• Adequate coagulation function, INR = 1.5 and a partial thromboplastin time (PTT) = 5 seconds above ULN

• Adequate contraception

• Signed informed consent

Exclusion Criteria:

• Untreated CNS metastases

• Prior bevacizumab therapy

• Radiologically documented evidence of major blood vessel invasion or encasement by cancer

• Prior systemic chemotherapy for Stage IIIB/IV NSCLC

• Prior systemic chemotherapy or radiation therapy for Stage I-IIIA NSCLC < 1 year prior

• Any concurrent malignancy other than basal cell skin cancer, or carcinoma in situ of the cervix

• Concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy

• Ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• Uncontrolled thrombotic or hemorrhagic disorders

• Poorly-controlled hypertension

• Chronic daily treatment with aspirin (> 325 mg/day) or other known inhibitors of platelet function

• History of gross hemoptysis (defined as bright red blood or = 1/2 teaspoon)

• Serious non-healing wound, ulcer, or bone fracture

• Undergone major surgery or subcutaneous venous access device placement. Post-operative bleeding complications or wound complications from a surgical procedures performed in the last 2 months

• Elective or a planned major surgery to be performed during the course of the trial

• Peripheral neuropathy = Grade 2 (National Cancer Institute Common Toxicity Criteria for Adverse Events, Version 3.0 [NCI-CTCAE v 3.0])

• If female, is pregnant or lactating

• Radiographic evidence of intratumor cavitation

• Grade 3-4 gastrointestinal bleeding within 3 months prior to study entry

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Biological:
• Ramucirumab
10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.

Drug:
• Paclitaxel
200 milligrams per meter squared (mg/m^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
• Carboplatin
Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.

Locations

Country	Name	City	State
United Kingdom	ImClone Investigational Site	Cambridge
United Kingdom	ImClone Investigational Site	London
United States	ImClone Investigational Site	Aurora	Colorado
United States	ImClone Investigational Site	Beverly Hills	California
United States	ImClone Investigational Site	Bronx	New York
United States	ImClone Investigational Site	New York	New York
United States	ImClone Investigational Site	San Antonio	Texas
United States	ImClone Investigational Site	San Francisco	California
United States	ImClone Investigational Site	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Are Progression-free (PFS) at 6 Months	Data presented are the percentage of participants without disease progression or death at 6 months. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Progressive disease was defined as having at least a 20% increase in sum of longest diameter of target lesions or the appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.	6 months	No
Secondary	Summary of Participants Reporting Adverse Events	Data presented are the number of participants who experienced ramucirumab related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of ramucirumab treatment, and any TEAE leading to dose modification ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.	Baseline up to 32.5 months	Yes
Secondary	Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate ([ORR])	Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST 1.0) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.	First dose to measured progressive disease or death due to any cause up to 32.5 months	No
Secondary	Duration of Response	The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression, initiation of additional antitumor therapy is first reported, or death as a result of any cause. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions.	First dose up to 32.5 months	No
Secondary	Overall Survival (OS) at 1 Year	Data presented are the percentage of participants surviving at least 12 months after first dose of study medication.	First dose to 1 year	No
Secondary	Progression-free Survival (PFS)	Defined as the time from date of first dose of study medication to the first documented disease progression as defined by Response Evaluation Criteria In Solid Tumors (RECIST 1.0), initiation of additional antitumor therapy was first reported or death due to any cause.; Participants who did not progress, who discontinued treatment for toxicity or a reason other than documented progression, or who were lost to follow-up before documented progression or death were censored at date of last tumor assessment. Participants who started new therapeutic anticancer treatment prior to documented progression or death were censored at date of last tumor assessment prior to new therapeutic anticancer therapy.	First dose to measured progressive disease or death due to any cause, up to 32.5 months	No
Secondary	Overall Survival (OS)	Overall survival is defined as the time from the first dose of study medication to the date of death from any cause. Participants who were alive at the end of the follow-up period or lost to follow-up were censored on the last date the patient was known to be alive.	First dose to death due to any cause, up to 32.5 months	No
Secondary	Serum Anti-Ramucirumab Antibody Assessment	The number of participants who developed treatment emergent antibody responses to ramucirumab after baseline.	Week 15 (Cycle 5)	Yes
Secondary	Maximum Concentration of Ramucirumab (Cmax)		Week 18 (Cycle 6), at 1-Hour Post End of Infusion	No